BCRX stock forecast
Our latest prediction for BioCryst Pharmaceuticals, Inc.'s stock price was made on the Dec. 4, 2018 when the stock price was at 8.89$.
In the short term (2weeks), BCRX's stock price should underperform the market by -0.18%. During that period the price should oscillate between -8.48% and +8.95%.
In the medium term (3months), BCRX's stock price should underperform the market by -0.59%. During that period the price should oscillate between -20.52% and +24.67%.Get email alerts
About BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases. Its drug candidates include rapivab, alpivab, rapiacta, peramiflu, BCX7353, BCX9930, BCX9250, Galidesivir, and Mundesine. The company was founded in 1986 and is headquartered in Durham, NC.
At the moment the company generates 22M USD in revenues.
On its last earning announcement, the company reported a loss of -0.93$ per share.
The book value per share is 0.42$
Three months stock forecastDec. 4, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|